207 related articles for article (PubMed ID: 23861169)
1. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study.
McCarthy AM; Bristol M; Fredricks T; Wilkins L; Roelfsema I; Liao K; Shea JA; Groeneveld P; Domchek SM; Armstrong K
Cancer; 2013 Oct; 119(20):3596-603. PubMed ID: 23861169
[TBL] [Abstract][Full Text] [Related]
2. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
3. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
4. Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
McCarthy AM; Bristol M; Domchek SM; Groeneveld PW; Kim Y; Motanya UN; Shea JA; Armstrong K
J Clin Oncol; 2016 Aug; 34(22):2610-8. PubMed ID: 27161971
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing.
Hall MJ; Reid JE; Wenstrup RJ
Cancer Prev Res (Phila); 2010 Dec; 3(12):1579-85. PubMed ID: 21149333
[TBL] [Abstract][Full Text] [Related]
6. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
[TBL] [Abstract][Full Text] [Related]
8. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.
Metcalfe KA; Finch A; Poll A; Horsman D; Kim-Sing C; Scott J; Royer R; Sun P; Narod SA
Br J Cancer; 2009 Jan; 100(2):421-5. PubMed ID: 19088722
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
12. What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2.
Adams I; Christopher J; Williams KP; Sheppard VB
J Cancer Educ; 2015 Jun; 30(2):344-52. PubMed ID: 25301325
[TBL] [Abstract][Full Text] [Related]
13. Feelings of Women With Strong Family Histories Who Subsequent to Their Breast Cancer Diagnosis Tested BRCA Positive.
Joseph M; Rab F; Panabaker K; Nisker J
Int J Gynecol Cancer; 2015 May; 25(4):584-92. PubMed ID: 25675043
[TBL] [Abstract][Full Text] [Related]
14. Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario.
Vanstone M; Chow W; Lester L; Ainsworth P; Nisker J; Brackstone M
Can Fam Physician; 2012 May; 58(5):e258-66. PubMed ID: 22734169
[TBL] [Abstract][Full Text] [Related]
15. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
Basu NN; Ingham S; Hodson J; Lalloo F; Bulman M; Howell A; Evans DG
Fam Cancer; 2015 Dec; 14(4):531-8. PubMed ID: 26239694
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
17. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
[TBL] [Abstract][Full Text] [Related]
18. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
19. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
20. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
